摘要
目的:探讨脑信号蛋白4D(Sema4D)对呼吸道合胞病毒(RSV)诱发哮喘大鼠炎症的影响及咳喘宁通过调节Sema4D对炎症的改善作用。方法:构建RSV复合卵清白蛋白(OVA)模型,实验大鼠随机分为正常组,模型组,咳喘宁低、中、高剂量组,Sema4D抗体组,予以相应药物干预。HE染色观察各组大鼠肺组织病理变化;免疫组化观察各组大鼠肺及脊髓组织Sema4D的表达;ELISA检测白细胞介素4(IL-4)、白细胞介素6(IL-6)、白细胞介素8(IL-8)、肿瘤坏死因子α(TNF-α)、干扰素γ(IFN-γ)的含量。结果:与正常组比较,其余各组Sema4D表达增多,IL-4、IL-6、IL-8、TNF-α含量较高,IFN-γ含量低(P<0.05,P<0.01);与模型组比较,各治疗组Sema4D的表达量及IL-4、IL-6、IL-8、TNF-α水平降低,IFN-γ水平升高(P<0.05,P<0.01)。结论:咳喘宁可能通过降低Sema4D的表达对免疫炎症进行调节,从而发挥治疗作用。
Objective:To investigate the effects of Sema4D on RSV-induced inflammation in asthmatic rats and the regulatory effect of Kechuanning on inflammation.Methods:RSV compound OVA model was constructed,and the experimental rats were randomly divided into the normal group,the model group,the low,medium and high dose group,the Sema4D antibody group,and corresponding drug intervention was given.Pathological changes of lung tissues in each group were observed by HE staining.The expression of Sema4D in lung and spinal cord tissues was observed by immunohistochemistry.The contents of IL-4,IL-6,IL-8,TNF-α,and IFN-γwere detected by ELISA.Results:Compared with the normal group,Sema4D expression was increased in other groups,with higher levels of IL-4,IL-6,IL-8,TNF-αand lower levels of IFN-γ(P<0.05,P<0.01).Compared with the model group,the levels of Sema4D,IL-4,IL-6,IL-8,and TNF-αin the treatment groups were lower,while the level of IFN-γwas higher(P<0.05,P<0.01).Conclusion:Kechuanning can regulate immune inflammation by reducing the expression of Sema4D,so as to play a therapeutic role.
作者
陈莹莹
李海霞
罗银河
王孟清
CHEN Ying-ying;LI Hai-xia;LUO Yin-he;WANG Meng-qing(Hunan University of Chinese Medicine,Changsha 410208,China;Hunan Children’s Hospital,Changsha 410007,China;Hunan University of Chinese Medicine(The Domestic First-class Discipline Construction Project of Chinese Medicine of Hunan University of Chinese Medicine),Changsha 410208,China;The First Hospital of Hunan University of Chinese Medicine,Changsha 410007,China)
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2020年第4期1724-1727,共4页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
国家自然科学基金项目(No.81674025,No.81774368)。